UP-421

Sana Biotechnology's HIP-modified islet cells demonstrated immune evasion and C-peptide production in a Type 1 Diabetes patient without immunosuppression.

Sana Biotechnology's UP421 islet cell therapy shows promising results in a Type 1 diabetes patient, marking a significant step towards a scalable, curative treatment without the need for immunosuppression.

Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression.

Morgan Stanley analyst Vikram Purohit reaffirms a Buy rating for Sana Biotechnology, citing promising interim results from the UP421 therapy in Type 1 Diabetes, which showed no adverse effects and evidence of immune evasion, indicating a strong proof of concept.

Sana Biotechnology's UP421 demonstrates survival and function of transplanted islet cells in a type 1 diabetes patient without immunosuppression.